<DOC>
	<DOCNO>NCT01724554</DOCNO>
	<brief_summary>The purpose study look effective , safe , well tolerated Intravitreal Aflibercept Injection subject Central Retinal Vein Occlusion ( CRVO ) Proliferative Diabetic Retinopathy ( PDR ) .</brief_summary>
	<brief_title>Impact Intravitreal Aflibercept Injections Capillary Non-Perfusion</brief_title>
	<detailed_description>Protocol available upon request .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>1 . Diagnosis one following : Proliferative retinopathy ( PDR ) Macular edema secondary CRVO Proliferative disease secondary CRVO ( anterior segment posterior segment neovascularization ) . 2 . Be need IAI treatment , whether previously treat treatmentnaïve . 3 . Age &gt; 18 year . 1 . Subjects macular edema secondary diabetic retinopathy without concomitant proliferative diabetic retinopathy . 2 . Subjects cataract medium opacity impair adequate visualization retina extent good quality image impossible . 3 . Presence substantial ocular disease ( diabetic retinopathy central retinal vein occlusion ) may compromise vision study eye /or confound interpretation data ; e.g . substantial cataract , advance glaucoma , optic neuritis , optic neuropathy atrophy , mark macular atrophy , history retinal detachment , uveitis , viral form chorioretinitis , etc . 4 . Active intraocular inflammation ( grade trace ) study eye , history idiopathic autoimmuneassociated uveitis either eye . 5 . Uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 25 mmHg despite treatment antiglaucoma medication ) . 6 . History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye . 7 . Participation study investigational drug device within 30 day prior potential enrollment study . 8 . Intraocular surgery ( include cataract surgery ) study eye within 60 day precede baseline . 9 . History vitrectomy surgery study eye . 10 . Subjects 12 antiVEGF injection within 24 month prior Screening . 11 . Subjects receive antiVEGF therapy within 30 day Screening received steroid laser therapy within 90 day Screening . 12 . Subjects allergic fluorescein , povidone iodine ( Betadyne ) aflibercept 13 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>